BROCK WOOTEN: Open Payments
NPI 1659116408 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$309 in 13 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $416 · 2025 $309
Food & beverage: $198Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $148 |
| Neurocrine BioSciences, Inc. | 2 | $31 |
| Alkermes, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| ABBVIE INC. | 1 | $14 |
Products named: REXULTI, UZEDY, VIVITROL, INVEGA SUSTENNA, SUBLOCADE, COBENFY, VRAYLAR, INGREZZA.
Industry payments across WA — which companies pay providers there.
